MYCO — Mydecine Innovations Cashflow Statement
0.000.00%
Last trade - 00:00- CA$0.62m
- CA$7.65m
Annual cashflow statement for Mydecine Innovations, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.9 | -23.6 | -17.2 | -20.9 | -3.15 |
| Depreciation | |||||
| Non-Cash Items | 18 | 3.89 | 0.474 | 11.4 | 0.752 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.77 | -4.59 | 8.21 | 5.3 | 2.36 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -7.12 | -24.1 | -8.43 | -4.22 | -0.037 |
| Capital Expenditures | -0.405 | -0.291 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.168 | -0.182 | -0.038 | 0.525 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.573 | -0.474 | -0.038 | 0.525 | 0 |
| Financing Cash Flow Items | — | -0.76 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.92 | 23.8 | 6.98 | 3.72 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.17 | -0.695 | -1.48 | 0.027 | -0.037 |